Overview

A Safety and Efficacy Study of Domvanalimab + Zimberelimab Combination Therapy in Participants With Advanced Upper Gastrointestinal Tract Malignancies

Status:
Not yet recruiting

Trial end date:
2024-05-28

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of the anti-T cell immunoglobulin and ITIM domain (TIGIT) monoclonal antibody domvanalimab, the anti-programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy in the first-line setting, and of domvanalimab and zimberelimab in the second-line or greater setting in participants with locally advanced unresectable or metastatic esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Arcus Biosciences, Inc.

Treatments:

Fluorouracil
Leucovorin
Oxaliplatin